Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

17. februar 2015 oppdatert av: Astellas Pharma Europe B.V.

A Double Blind, Randomized, Placebo-controlled, Ascending Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1707 in Healthy Young and Elderly Male Subjects and in Healthy Pre-menopausal Female Subjects Including an Open-label Comparison of Pharmacokinetics Under Fasted and Fed Conditions in Healthy Young Male Subjects

This study consists of four parts:

Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy young male subjects to evaluate the safety, tolerability pharmacokinetics (PK) and effect on certain hormones and if possible to determine the highest well-tolerated dose of ASP1707 in healthy young male subjects under fasted conditions.

Part 2 is an open label, randomized crossover, single dose study to determine the effect of food on the pharmacokinetics of ASP1707and effect on certain hormones in healthy young male subjects.

Part 3 is a randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics (PK) of ASP1707 in healthy elderly men and healthy premenopausal females, and to determine the effect on certain hormones in males. Age and gender is also evaluated.

Part 4 is a randomized, double-blind, placebo-controlled, parallel, multiple dose study to evaluate the safety, tolerability and PK of ASP1707, and its effect on certain hormones in healthy pre-menopausal female subjects.

Studieoversikt

Detaljert beskrivelse

Part 1 comprises 7 dose groups of 8 healthy young male subjects. ASP1707 or matching placebo ( 3 to 1 ratio) is given as a single dose under fasted conditions.

The first group receives the lowest dose while the last group receives the highest dose.

Part 2 (Food-Effect) The group consists of 12 healthy young male subjects who receive two separate doses of ASP1707 under fasted or fed conditions. Half of the subjects are dosed first under fasted condition and half of them had first an FDA high-fat breakfast. Subjects receive the alternate treatment on the second occasion. Dosing is separated by at least 7 days or 7 times t1/2 (terminal elimination half-life) as assessed from Part 1.

Part 3 Comprises 4 dose groups of 12 healthy elderly men each, and two groups of 12 healthy premenopausal women. The latter are dosed ASP1707 or placebo in parallel to the 4 male groups. Subjects are fasted or fed depending on observations from Part 2.

Dose levels are defined after evaluating interim safety, tolerability and PK and PD results from Part 1. A lower maximum dose is used in women than in men, based on preclinical data. Dose escalation in the men is independent from dose escalation in the women. Women and men receive once-daily dosing;

Part 4 includes 4 groups, 1 placebo and 3 for ASP1707, each with 9 pre-menopausal women. Subjects in each dose group receive a fixed daily dose. Subjects are domiciled for various intervals during each of 3 menstrual cycles. Dosing occurs for 21 Days during the subjects' second menstrual cycle of the study (Day 1 of Period 2); fasted or fed depending on observations from Part 2.

Studietype

Intervensjonell

Registrering (Faktiske)

176

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Paris, Frankrike, 75015
        • SGS Life Science Services, Aster

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Parts 1 & 2:

  • Healthy young male subject aged 18 to 45 years inclusive
  • Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
  • Male subjects must be non-fertile, or must practice an adequate contraceptive method to prevent pregnancies.

Part 3:

  • Healthy elderly male subject aged 55 years or older, or healthy pre-menopausal female subject aged 18 to 45 inclusive.
  • Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
  • Male subject must be non-fertile, or must practice adequate contraceptive methods.
  • Female subjects must be of non-child bearing potential, i.e. surgically sterilized or practice adequate (double barrier) non-hormonal contraceptive methods.

Part 4:

  • Healthy pre-menopausal female subject aged 18 to 45 inclusive.
  • Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
  • Female subjects must be of non-child bearing potential, i.e. surgically sterilized or practice adequate contraceptive methods.
  • Females having a regular menstruation cycle with a duration between 25 up to 30 days.

Exclusion Criteria:

Parts 1 & 2:

  • Male subjects with out-of-range Testosterone levels in serum at screening.
  • Subjects with any history of cancer.
  • Any of the liver function tests (i.e. ALT and AST) above the upper limit of normal.
  • A QTc interval of > 430 ms after repeated measurements.
  • Regular use of any inducer of metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
  • Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.

Part 3:

  • Pregnancy within 6 months before screening assessment or breast feeding 3 months before screening.
  • Male subjects with out-of-range T levels in serum at screening.
  • Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.

Part 4:

  • Pregnancy within 6 months before screening assessment or breast feeding 3 months before screening.
  • Use of any hormonal interfering contraceptives in the 3 months before admission (for 3 consecutive menstruation cycles) OR any evidence of unovulatory menstrual cycles.
  • Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 1. Single ascending dose (SAD), ASP1707 dose levels 1-7
healthy young male
Oral, dose escalation
Eksperimentell: 2. Single ascending dose (SAD), placebo dose levels 1-7
healthy young male
Oral, dose escalation, healthy young male
Eksperimentell: 3. Food effect (FE), ASP1707 fasted
Fasted healthy young male
Oral, healthy young male
Eksperimentell: 4. Food effect (FE), ASP1707 fed
Fed healthy young male
Oral, healthy young male
Eksperimentell: 5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4
healthy elderly male
Oral, multiple dose escalation, healthy elderly male
Eksperimentell: 6. Multiple ascending dose (MAD), Placebo, dose levels 1-4
healthy elderly male
Oral, multiple dose escalation, healthy elderly male
Eksperimentell: 7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2
healthy pre-menopausal female
Oral, multiple dose escalation, healthy pre-menopausal female
Eksperimentell: 8. Multiple ascending dose (MAD), Placebo dose levels 1-2
healthy pre-menopausal female
Oral, multiple dose escalation, healthy pre-menopausal female
Eksperimentell: 9. Parallel multiple dose, ASP1707 dose levels 1-3
healthy pre-menopausal female
Oral, multiple dose, healthy pre-menopausal female
Eksperimentell: 10. Parallel multiple dose, Placebo
healthy pre-menopausal female
Oral, dose escalation, healthy pre-menopausal female

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety assessed by nature, frequency and severity of adverse events
Tidsramme: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Respectively Part 1 and Part 3
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Safety assessed by physical examination
Tidsramme: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Respectively Part 1 and Part 3
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Safety assessed by vital signs
Tidsramme: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Respectively Part 1 and Part 3. Vital signs include blood pressure and pulse.
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Safety assessed by safety laboratory tests
Tidsramme: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Respectively Part 1 and Part 3, Biochemistry, hematology, and urinalysis
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Safety assessed by 12 lead electrocardiogram (ECG)
Tidsramme: Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Respectively Part 1 and Part 3
Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)
Safety assessed by continuous cardiac monitoring (Holter)
Tidsramme: Days -1 and 21
Part 3
Days -1 and 21
Pharmacokinetics (PK) of ASP1707 measured by area under the plasma concentration - time curve (AUC) extrapolated to time = infinity (AUCinf) in plasma
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by area under the plasma concentration-time curve (AUC) to time from the time of dosing to the last measurable concentration (AUClast) in plasma
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by time to reach quantifiable concentrations (tlag) in plasma
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by time to attain maximum concentration (tmax) in plasma
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by Cmax in plasma
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by terminal elimination half-life (t1/2) in plasma
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by apparent volume of distribution (Vz/F) in plasma
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by apparent clearance (CL/F) in plasma
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by amount excreted unchanged into urine (Ae) from time of dosing until last measurable concentration (Aelast) in urine
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by Ae extrapolated to time = infinity (Aeinf) in urine
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by Ae in % up to the collection time of the last measurable concentration (Aelast%) in urine
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by Ae in % extrapolated to time infinity (Aeinf%) in urine
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
PK of ASP1707 measured by renal clearance (CLR) in urine
Tidsramme: Pre-dose (Day 1) to Day 5
Part 2
Pre-dose (Day 1) to Day 5
Pharmacodynamics (PD) of ASP1707 measured by Cmax in plasma
Tidsramme: Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3
Part 4, period 1, 2 and 3. Estradiol (E2), Follicle-stimulating hormone (FSH) and Luteinizing Hormone (LH) levels
Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3
PD of ASP1707 measured by tmax in plasma
Tidsramme: Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3
Part 4, period 1, 2 and 3. E2, FSH and LH levels
Day -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3
PD of ASP1707 measured by average concentration (Cavg, day 7-15) in plasma
Tidsramme: Pre-dose to Day 26
Part 4, period 1, 2 and 3. E2, FSH and LH levels
Pre-dose to Day 26
PD of ASP1707 measured by average concentration (Cavg, day 5-19) in plasma
Tidsramme: Pre-dose to Day 26
Part 4, period 3. E2, FSH and LH levels
Pre-dose to Day 26
PD of ASP1707 measured by average concentration (Cavg, day 23-26) in plasma
Tidsramme: Pre-dose to Day 26
Part 4, period 2. E2, FSH and LH levels
Pre-dose to Day 26
PD of ASP1707 - maximal duration within therapeutic range
Tidsramme: Pre-dose to Day 26
Part 4, period 2. E2 levels
Pre-dose to Day 26
PD of ASP1707 - total duration within therapeutic range (20-50 pg/mL)
Tidsramme: Pre-dose to Day 26
Part 4, period 2. E2 levels
Pre-dose to Day 26
PD of ASP1707 - Time of onset therapeutic range
Tidsramme: Pre-dose to Day 26
Part 4, period 2. E2 levels
Pre-dose to Day 26
PD of ASP1707 - Time of offset therapeutic range
Tidsramme: Pre-dose to Day 26
Part 4, period 2. E2 levels
Pre-dose to Day 26
PD of ASP1707 - Time of start menstruation after last dose of study drug
Tidsramme: Pre-dose to Day 26
Part 4, period 3
Pre-dose to Day 26

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
PK profile of ASP1707 in plasma and urine for Part 1
Tidsramme: Pre-dose (Day 1) to Day 5
AUCinf, AUClast, tlag, tmax, Cmax, t1/2, Vz/F, CL/F, Aelast, Aeinf, Aelast%, Aeinf%, CLR
Pre-dose (Day 1) to Day 5
Safety profile assessed by nature, frequency and severity of adverse events, physical examination, vital signs, safety laboratory tests and 12 lead ECG
Tidsramme: Screening to End of Study Visit (ESV) (Up to 31 days and up to 62 days)
Respectively Part 2 and Part 4
Screening to End of Study Visit (ESV) (Up to 31 days and up to 62 days)
PD profile of ASP1707 for Part 1 and Part 2
Tidsramme: Pre-dose (Day 1) to Day 12-19
Testosterone (T), LH and FSH levels: Cmin, tmin, maximal %Reduction and T only: Number and percentage of subjects with T castration level (= T < 0.5 ng/mL) after single dose, Time of onset of T < 0.5 ng/mL after single dose, Duration of T <0.5 ng/mL after single dose
Pre-dose (Day 1) to Day 12-19
PD profile of ASP1707 for Part 3
Tidsramme: Pre-dose (Day 1) to Day 39
T, LH and FSH levels: Cmin, tmin, maximal %Reduction T only: Number and percentage of subjects with T < 0.5 ng/mL at any time post-first dose, Number and percentage of subjects with T < 0.5 ng/mL after last dose, Number of subjects reaching T<0.5 ng/mL for ≥14 days, Day of onset of T < 0.5 ng/mL after multiple doses of ASP1707 (T < 0.5 ng/mL for the first time), Time of onset of T < 0.5 ng/mL after first dose, Duration of T < 0.5 ng/mL after single dose and during multiple dosing, Total duration, Maximal duration:Time from last dose to return to baseline levels for T, LH and FSH, Duration of T < 0.5 ng/mL after last dose
Pre-dose (Day 1) to Day 39
PK profile of ASP1707 in plasma and urine for Part 3
Tidsramme: Pre-dose (Day 1) to Day 25
AUCinf, AUClast, tlag, tmax, Cmax, t1/2, Vz/F, CL/F, Aelast, Aeinf, Aelast%, Aeinf%, CLR, Ctrough, AUC during the time interval between consecutive dosing (AUCtau), Accumulation Ratio (Rac), Peak Trough Ratio (PTR), Ae during the time interval between consecutive dosing (Aetau), Aetau as percentage of total dose (Aetau%), Ae during the time interval between consecutive dosing (AUCtau), (AUC0-24h), Ae0-24h, Ae0-24h%
Pre-dose (Day 1) to Day 25
PK profile of ASP1707 in plasma and urine for Part 4
Tidsramme: Pre-dose (Day 23) to Day 25
AUCtau, tmax, Cmax, t1/2, Vz/F, CL/F, CLR, Ctrough, PTR, Aetau, Aetau%,
Pre-dose (Day 23) to Day 25

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. juni 2010

Primær fullføring (Faktiske)

1. august 2011

Studiet fullført (Faktiske)

1. august 2011

Datoer for studieregistrering

Først innsendt

14. november 2014

Først innsendt som oppfylte QC-kriteriene

17. februar 2015

Først lagt ut (Anslag)

23. februar 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

23. februar 2015

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. februar 2015

Sist bekreftet

1. februar 2015

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 1707-CL-0001
  • 2010-018292-21 (EudraCT-nummer)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere